BR112015012730A2 - compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos - Google Patents
compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicosInfo
- Publication number
- BR112015012730A2 BR112015012730A2 BR112015012730A BR112015012730A BR112015012730A2 BR 112015012730 A2 BR112015012730 A2 BR 112015012730A2 BR 112015012730 A BR112015012730 A BR 112015012730A BR 112015012730 A BR112015012730 A BR 112015012730A BR 112015012730 A2 BR112015012730 A2 BR 112015012730A2
- Authority
- BR
- Brazil
- Prior art keywords
- beta2
- compounds
- agonist activity
- adrenergic receptor
- muscarinic
- Prior art date
Links
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 title abstract 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title abstract 3
- 239000000048 adrenergic agonist Substances 0.000 title abstract 3
- 229940126157 adrenergic receptor agonist Drugs 0.000 title abstract 3
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 239000003149 muscarinic antagonist Substances 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
resumo compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos a presente invenção se refere a compostos que atuam tanto como antagonistas de receptores muscarínicos quanto como agonistas de receptores beta2-adrenérgicos, aos processos para sua preparação, às composições que os compreendem, aos usos terapêuticos e às combinações com outros ingredientes farmaceuticamente ativos. 1/1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195891.2 | 2012-12-06 | ||
| EP12195891 | 2012-12-06 | ||
| PCT/EP2013/075661 WO2014086924A1 (en) | 2012-12-06 | 2013-12-05 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015012730A2 true BR112015012730A2 (pt) | 2017-07-11 |
| BR112015012730B1 BR112015012730B1 (pt) | 2022-07-05 |
Family
ID=47323975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015012730-4A BR112015012730B1 (pt) | 2012-12-06 | 2013-12-05 | Composto, composição farmaceutica, dispositivo, uso de um composto e combinação |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US8987299B2 (pt) |
| EP (2) | EP2928889B1 (pt) |
| JP (1) | JP6421989B2 (pt) |
| KR (2) | KR102240459B1 (pt) |
| CN (1) | CN104822678B (pt) |
| AR (1) | AR093825A1 (pt) |
| AU (1) | AU2013354043C1 (pt) |
| BR (1) | BR112015012730B1 (pt) |
| CA (1) | CA2893626C (pt) |
| CL (1) | CL2015001483A1 (pt) |
| CO (1) | CO7400870A2 (pt) |
| CY (2) | CY1120159T1 (pt) |
| DK (2) | DK2928889T3 (pt) |
| EA (1) | EA030552B1 (pt) |
| ES (2) | ES2670686T3 (pt) |
| GE (1) | GEP20186839B (pt) |
| HR (2) | HRP20180915T1 (pt) |
| HU (2) | HUE037944T2 (pt) |
| IL (1) | IL239182B (pt) |
| LT (2) | LT2928889T (pt) |
| MA (1) | MA38147B1 (pt) |
| MX (1) | MX369311B (pt) |
| NZ (1) | NZ708738A (pt) |
| PE (1) | PE20151216A1 (pt) |
| PH (1) | PH12015501247B1 (pt) |
| PL (2) | PL3345904T3 (pt) |
| PT (2) | PT2928889T (pt) |
| RS (2) | RS57232B1 (pt) |
| SA (1) | SA515360514B1 (pt) |
| SG (2) | SG10201704032RA (pt) |
| SI (2) | SI3345904T1 (pt) |
| TN (1) | TN2015000244A1 (pt) |
| TR (1) | TR201808698T4 (pt) |
| TW (1) | TWI637954B (pt) |
| UA (1) | UA118181C2 (pt) |
| WO (1) | WO2014086924A1 (pt) |
| ZA (1) | ZA201503965B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| DK2928889T3 (en) * | 2012-12-06 | 2018-05-22 | Chiesi Farm Spa | Compounds with muscarinic receptor antagonist and beta2-adrenergic receptor antagonist activity |
| RU2661877C2 (ru) * | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
| US9518050B2 (en) | 2012-12-18 | 2016-12-13 | Almirall, S.A. | Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| TWI703138B (zh) * | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| AR104828A1 (es) * | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO |
| EA037716B1 (ru) * | 2015-11-16 | 2021-05-13 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ получения сухой порошковой композиции, содержащей антихолинергическое средство, кортикостероид и бета-адренергическое средство, порошковая композиция, ингалятор, применение сухой порошковой композиции для профилактики и/или лечения воспалительного и/или обструктивного заболевания дыхательных путей |
| WO2017093208A1 (en) | 2015-12-03 | 2017-06-08 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| EP3484879B1 (en) | 2016-07-13 | 2020-12-30 | Chiesi Farmaceutici S.p.A. | Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| CA2994290C (en) | 2017-11-06 | 2024-01-23 | Entech Solution As | Method and stimulation sleeve for well completion in a subterranean wellbore |
| EP4263528A1 (en) * | 2020-12-21 | 2023-10-25 | Intervet International B.V. | A process for the preparation of n-(bis(4-methoxyphenyl)methyl)-6-oxo-2-(pyridazin-3-yl)-1,6-dihydropyrimidine-5-carboxamide |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2222128A (en) | 1937-01-29 | 1940-11-19 | Pure Oil Co | Preparation and separation of aromatic hydrocarbons |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| PL376396A1 (en) | 2002-10-11 | 2005-12-27 | Pfizer Inc. | Indole derivatives as beta-2 agonists |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| DE602004021959D1 (de) | 2003-11-21 | 2009-08-20 | Theravance Inc | Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor |
| EP1708992B1 (en) | 2004-01-22 | 2007-08-08 | Pfizer Limited | Sulfonamide derivatives for the treatment of diseases |
| WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| AP2315A (en) | 2004-03-23 | 2011-11-04 | Pfizer | Formamide derivatives useful as adrenoceptor. |
| US7538141B2 (en) | 2004-03-23 | 2009-05-26 | Alan Daniel Brown | Compounds for the treatment of diseases |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| JP2008510014A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| EP1833822A2 (en) | 2004-08-16 | 2007-09-19 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| FR2898640B1 (fr) | 2006-03-20 | 2008-04-25 | Siemens Vdo Automotive Sas | Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne |
| EP2080523A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| PT2421849E (pt) | 2009-04-23 | 2013-05-27 | Theravance Inc | Compostos de diamida tendo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta2 |
| WO2010126025A1 (ja) * | 2009-04-30 | 2010-11-04 | 帝人ファーマ株式会社 | 四級アンモニウム塩化合物 |
| WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| EP2718280B1 (en) * | 2011-06-10 | 2015-09-16 | Chiesi Farmaceutici S.p.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| WO2012168349A1 (en) | 2011-06-10 | 2012-12-13 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| RU2661877C2 (ru) * | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
| DK2928889T3 (en) * | 2012-12-06 | 2018-05-22 | Chiesi Farm Spa | Compounds with muscarinic receptor antagonist and beta2-adrenergic receptor antagonist activity |
-
2013
- 2013-12-05 DK DK13811827.8T patent/DK2928889T3/en active
- 2013-12-05 SI SI201331764T patent/SI3345904T1/sl unknown
- 2013-12-05 SG SG10201704032RA patent/SG10201704032RA/en unknown
- 2013-12-05 JP JP2015546012A patent/JP6421989B2/ja active Active
- 2013-12-05 ES ES13811827.8T patent/ES2670686T3/es active Active
- 2013-12-05 KR KR1020207006181A patent/KR102240459B1/ko active Active
- 2013-12-05 EP EP13811827.8A patent/EP2928889B1/en active Active
- 2013-12-05 PL PL18156043T patent/PL3345904T3/pl unknown
- 2013-12-05 TR TR2018/08698T patent/TR201808698T4/tr unknown
- 2013-12-05 LT LTEP13811827.8T patent/LT2928889T/lt unknown
- 2013-12-05 HU HUE13811827A patent/HUE037944T2/hu unknown
- 2013-12-05 UA UAA201505478A patent/UA118181C2/uk unknown
- 2013-12-05 LT LTEP18156043.4T patent/LT3345904T/lt unknown
- 2013-12-05 EA EA201590873A patent/EA030552B1/ru unknown
- 2013-12-05 GE GEAP201313845A patent/GEP20186839B/en unknown
- 2013-12-05 CA CA2893626A patent/CA2893626C/en active Active
- 2013-12-05 AU AU2013354043A patent/AU2013354043C1/en not_active Ceased
- 2013-12-05 PT PT138118278T patent/PT2928889T/pt unknown
- 2013-12-05 MX MX2015006788A patent/MX369311B/es active IP Right Grant
- 2013-12-05 KR KR1020157014956A patent/KR102156443B1/ko not_active Expired - Fee Related
- 2013-12-05 WO PCT/EP2013/075661 patent/WO2014086924A1/en active Application Filing
- 2013-12-05 BR BR112015012730-4A patent/BR112015012730B1/pt active IP Right Grant
- 2013-12-05 PL PL13811827T patent/PL2928889T3/pl unknown
- 2013-12-05 RS RS20180529A patent/RS57232B1/sr unknown
- 2013-12-05 HR HRP20180915TT patent/HRP20180915T1/hr unknown
- 2013-12-05 CN CN201380063365.2A patent/CN104822678B/zh active Active
- 2013-12-05 SI SI201330994T patent/SI2928889T1/en unknown
- 2013-12-05 AR ARP130104529A patent/AR093825A1/es unknown
- 2013-12-05 PT PT181560434T patent/PT3345904T/pt unknown
- 2013-12-05 MA MA38147A patent/MA38147B1/fr unknown
- 2013-12-05 TW TW102144561A patent/TWI637954B/zh not_active IP Right Cessation
- 2013-12-05 RS RS20201150A patent/RS60864B1/sr unknown
- 2013-12-05 NZ NZ708738A patent/NZ708738A/en not_active IP Right Cessation
- 2013-12-05 EP EP18156043.4A patent/EP3345904B1/en active Active
- 2013-12-05 SG SG11201504318UA patent/SG11201504318UA/en unknown
- 2013-12-05 PE PE2015000738A patent/PE20151216A1/es active IP Right Grant
- 2013-12-05 HU HUE18156043A patent/HUE051394T2/hu unknown
- 2013-12-05 DK DK18156043.4T patent/DK3345904T3/da active
- 2013-12-05 ES ES18156043T patent/ES2816210T3/es active Active
- 2013-12-06 US US14/098,735 patent/US8987299B2/en active Active
-
2015
- 2015-01-23 US US14/603,926 patent/US9371318B2/en active Active
- 2015-06-02 CL CL2015001483A patent/CL2015001483A1/es unknown
- 2015-06-03 TN TNP2015000244A patent/TN2015000244A1/fr unknown
- 2015-06-03 CO CO15127118A patent/CO7400870A2/es unknown
- 2015-06-03 IL IL239182A patent/IL239182B/en active IP Right Grant
- 2015-06-03 SA SA515360514A patent/SA515360514B1/ar unknown
- 2015-06-03 PH PH12015501247A patent/PH12015501247B1/en unknown
- 2015-06-03 ZA ZA2015/03965A patent/ZA201503965B/en unknown
-
2018
- 2018-05-03 CY CY20181100469T patent/CY1120159T1/el unknown
-
2020
- 2020-09-09 HR HRP20201435TT patent/HRP20201435T1/hr unknown
- 2020-09-28 CY CY20201100912T patent/CY1123365T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015012746A2 (pt) | compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos | |
| BR112015012730A2 (pt) | compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos | |
| PH12013502551A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| PH12017501424B1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| PH12014500355A1 (en) | Lysophosphatidic acid receptor antagonists | |
| CR20140182A (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenérgicos b2 y como antagonistas muscarínicos m3 | |
| ECSP14013340A (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenérgicos ?2 y como antagonistas muscarínicos m3 | |
| CR20150322A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3 | |
| UY32734A (es) | Compuestos agonistas del receptor esfingosina 1-fosfato | |
| NI201500080A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3. | |
| CR20140257A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
| BR112017023484A2 (pt) | compostos tendo atividade de antagonista de receptor muscarínico e agonista de receptor beta2 adrenérgico | |
| BR112013025682A2 (pt) | Compostos, composição farmacêutica, uso de um composto, combinação e dispositivo | |
| TN2013000429A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| UA109581C2 (uk) | Сполуки з активністю антагоністів мускаринових рецепторів і агоністів адренергічного рецептора бета2 | |
| ECSP15026152A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas beta2 adrenérgicos y como antagonistas muscarínicos m3 | |
| BR112018075817A2 (pt) | composto de fórmula (i), medicamento e composição farmacêutica | |
| BR112015015491A2 (pt) | compostos (tieno[2,3-b][1,5] benzoxazepin-4-il) piperazin-1-ila com atividade dual como agonistas inversos h1/antagonistas 5-ht2a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 453/02 Ipc: C07D 453/02 (2006.01), A61K 31/439 (2006.01), A61K |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2013, OBSERVADAS AS CONDICOES LEGAIS |